Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Leases (2019 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Operating Leases readings, the most recent being $5.9 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 23.19% to $5.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $5.9 million, a 23.19% decrease, with the full-year FY2025 number at $6.5 million, down 17.2% from a year prior.
  • Operating Leases hit $5.9 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $6.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $11.3 million in Q2 2023 to a low of $1.3 million in Q2 2022.
  • Median Operating Leases over the past 5 years was $7.2 million (2025), compared with a mean of $6.7 million.
  • Biggest five-year swings in Operating Leases: tumbled 63.49% in 2022 and later surged 782.86% in 2023.
  • Kiniksa Pharmaceuticals International's Operating Leases stood at $2.6 million in 2022, then soared by 282.16% to $10.0 million in 2023, then decreased by 21.42% to $7.9 million in 2024, then fell by 17.2% to $6.5 million in 2025, then dropped by 10.06% to $5.9 million in 2026.
  • The last three reported values for Operating Leases were $5.9 million (Q1 2026), $6.5 million (Q4 2025), and $7.0 million (Q3 2025) per Business Quant data.